I have let off steam.
Now for some logic discussion, some points to note:
1.I have said time and time again over the last few years that Teva is a generic company. We need to partnering with a Pharma that is in the CHF space. We have an opportunity to do this now.
2. We have no evidence to beleive that the science is not working. In fact we have the oppositive, we have had the tick of approval to continue with the trial from the data monitoring comittee
3. Whilst again i beleive the firm has been poor in its comms, and knew this was comiong for a long time. Si is right in saying that if the science works, MSB will benefit a lot more by going on its own.
4. As far as i am concerned there is only one immediate issue and that is funding. And apparently that has been resolved.
So whats the problem?
-
- There are more pages in this discussion • 122 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.67 |
Change
0.015(0.91%) |
Mkt cap ! $2.133B | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.67 | $1.63 | $3.655M | 2.203M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 48000 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.67 | 98565 | 7 |
View Market Depth
| Last trade - 16.10pm 14/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |